SCHEMBL4423658

SCHEMBL4423658

O=C(Nc1ccc(N2CCOCC2)c(F)c1)C1C2CN(Cc3ccc(Oc4ccccc4)cc3)CC21

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.50
RAB9A P51151 6/20 0.50
MAPT P10636 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
LTA4H P09960 2/20 0.48
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 3/20 0.47
HPGD P15428 2/20 0.47
F10 P00742 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
TP53 P04637 1/20 0.45
HTT P42858 2/20 0.44
FAAH O00519 1/20 0.44
DGAT1 O75907 1/20 0.44
NPY2R P49146 1/20 0.43
GAA P10253 1/20 0.43
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4414134 0.93 ALDH1A1 (0.49) NPC1RAB9AMAPTL3MBTL1KMT2A
SCHEMBL4415238 0.90 HIF1A (0.52) NPC1RAB9AMAPTL3MBTL1KMT2A
SCHEMBL4412368 0.89 MAPT (0.53) NPC1RAB9AMAPTL3MBTL1KMT2A
SCHEMBL4411172 0.88 ABL1 (0.50) NPC1RAB9AMAPTL3MBTL1KMT2A
SCHEMBL4413542 0.88 MCHR1 (0.55) NPC1RAB9AMAPTL3MBTL1KMT2A
SCHEMBL4417594 0.88 L3MBTL1 (0.48) NPC1RAB9AMAPTL3MBTL1KMT2A
SCHEMBL4424930 0.87 L3MBTL1 (0.45) NPC1RAB9AMAPTL3MBTL1KMT2A
SCHEMBL2170675 0.87 L3MBTL1 (0.52) NPC1RAB9AMAPTL3MBTL1KMT2A
SCHEMBL4413305 0.87 L3MBTL1 (0.55) NPC1RAB9AMAPTL3MBTL1ALDH1A1
SCHEMBL4425283 0.86 MAPT (0.48) NPC1RAB9AMAPTL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 NPC1 301/4885RAB9A 816/4885MAPT 1368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.